HIGHLIGHTS
- who: Mehrdad Zarei from the Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Euclid Ave, Cleveland, OH, USA have published the article: Wild-type IDH1 inhibition enhances chemotherapy response in melanoma, in the Journal: (JOURNAL)
- what: If true, this work provides a strong rationale to translate findings to clinical trials that test the combination of available wtIDH1 inhibitors with conventional chemotherapeutics largely abandoned for patients with advanced melanoma (e_g, DTIC or TMZ). The authors show here that wtIDH1 is a compelling therapeutic target in this regard because it is a metabolic . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.